AGM
ADMS

Alpine Global Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Alpine Global Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,581
Closed -$54K – 402
2020
Q4 		$54K Buy
+12,581
New +$53.8K 0.01% 191

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Alpine Global Management's ADMS Position: Q1 2021 in Review

Alpine Global Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 12,581 shares — an estimated $54K sold.

Alpine Global Management first reported a position in ADMS in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • Alpine Global Management reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Alpine Global Management sold 12,581 Adamas Pharmaceuticals shares in Q1 2021, an estimated $54K.
  • Alpine Global Management first reported a position in Adamas Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Alpine Global Management's Adamas Pharmaceuticals position peaked at $54K in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on Alpine Global Management's 13F filing for Q1 2021, filed 13 May 2021.